Most importantly, our data showed that the BNT162b2 vaccine induced a significantly higher CD4+ and CD8+ T-cell (Ag2) response after the second vaccination compared to the BBIBP-CorV vaccine in cancer patients. This evidence concerns the gene CD8A and cancer.